Answers are grounded in this paper and cite their sources.
Background Average acceleration derived from wearable sensors offers a simple, continuous measure of physical activity and mobility that may overcome the limitations of complex accelerometer algorithms or site-based assessments in clinical trials. However, evidence supporting the use of average acceleration in patients with heart failure (HF) and/or chronic obstructive pulmonary disease (COPD) remains limited. Objective This study aimed to evaluate how average acceleration can be used to assess walking-related outcomes in both laboratory and free-living settings and to assess the influence of sensor location on these measurements in participants with HF or COPD and healthy volunteers. Methods Using data from the Mobilise-D Technical Validation Study, including structured, laboratory-based tasks and free-living assessments using sensors placed on the foot, lower back, and wrist, we analyzed average acceleration metrics computed as Euclidean norm minus one (ENMO), ENMO >0, and Euclidean norm (EN) from band-pass filtered triaxial acceleration (0.29-10 Hz; fourth-order Butterworth). During walking bouts, average acceleration was correlated with walking speed and cadence for each sensor location and cohort (HF, COPD, and healthy adults); sensor-location effects and cohort-specific sensitivity were evaluated. Linear mixed-effects models included participants as random intercepts and walking speed as both a fixed effect and a random effect. Results Average acceleration showed a strong positive association with walking speed during straight-walking laboratory tasks across all sensor locations, with foot sensors showing the strongest association, followed by lower-back sensors and then wrist sensors. In complex walking tasks and free-living walking bouts, the strength of these associations decreased, and location effects were more pronounced. Across cohorts during free living, filtered EN r 2 ranged from 0.711 to 0.818 for the foot, from 0.439 to 0.673 for the lower back, and from 0.067 to 0.146 for the wrist. The strength of the association for wrist data improved only during free-living sustained walking bouts (>10 seconds), although these associations were weaker than those for the foot and lower back. The Pearson correlation was marginally stronger for ENMO >0 than for filtered EN, but filtered EN preserved more signal by mitigating the influence of gravity and noise. Linear mixed-effects models showed that the variance could be largely attributed to stable participant-specific differences. Conclusions Average acceleration showed potential as a measure for capturing walking-related activity in adults with HF or COPD and in healthy adults when using appropriate sensor placement. The strength of the association depended strongly on sensor placement, with the foot showing the most consistent relationship, the lower back providing a reasonable alternative, and the wrist showing weaker performance, particularly during free living. We recommend that trials use standardized reporting of sensor location, filtering parameters, and walking-bout definitions and prioritize foot or lower-back placement for walking-related end points.
No takes yet. Share an insight, caveat, or question.
Sillén et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: